Jefferies Financial Group Comments on Sanofi SA’s Q3 2018 Earnings (SNY)
Sanofi SA (NYSE:SNY) – Research analysts at Jefferies Financial Group issued their Q3 2018 earnings per share estimates for Sanofi in a research note issued on Friday, October 12th. Jefferies Financial Group analyst I. Hilliker anticipates that the company will post earnings per share of $0.97 for the quarter. Jefferies Financial Group also issued estimates for Sanofi’s FY2019 earnings at $3.20 EPS, FY2020 earnings at $3.52 EPS, FY2021 earnings at $3.82 EPS and FY2022 earnings at $4.10 EPS.
A number of other brokerages have also recently issued reports on SNY. Zacks Investment Research cut shares of Sanofi from a “hold” rating to a “sell” rating in a research note on Tuesday. Guggenheim began coverage on shares of Sanofi in a research note on Monday, October 8th. They issued a “neutral” rating for the company. BNP Paribas raised shares of Sanofi from a “neutral” rating to an “outperform” rating in a research note on Wednesday, August 1st. Deutsche Bank reiterated a “buy” rating on shares of Sanofi in a report on Wednesday, August 1st. Finally, Argus upped their price target on shares of Sanofi from $46.00 to $48.00 and gave the company a “buy” rating in a report on Friday, August 24th. Four research analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $49.00.
Sanofi (NYSE:SNY) last announced its quarterly earnings data on Tuesday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.72 by $0.02. Sanofi had a net margin of 10.29% and a return on equity of 23.77%. The company had revenue of $8.18 billion during the quarter, compared to analysts’ expectations of $8.27 billion. During the same quarter in the prior year, the company earned $1.35 EPS. The firm’s revenue was down 5.6% on a year-over-year basis.
In related news, major shareholder Sanofi sold 104,552 shares of the company’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $406.68, for a total transaction of $42,519,207.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.00% of the company’s stock.
A number of large investors have recently bought and sold shares of SNY. Fisher Asset Management LLC raised its holdings in Sanofi by 3.6% in the 2nd quarter. Fisher Asset Management LLC now owns 15,622,562 shares of the company’s stock worth $625,059,000 after purchasing an additional 549,110 shares in the last quarter. BlackRock Inc. raised its holdings in Sanofi by 0.7% in the 2nd quarter. BlackRock Inc. now owns 3,328,180 shares of the company’s stock worth $133,161,000 after purchasing an additional 22,425 shares in the last quarter. Brandes Investment Partners LP raised its holdings in Sanofi by 5.0% in the 2nd quarter. Brandes Investment Partners LP now owns 2,851,133 shares of the company’s stock worth $114,074,000 after purchasing an additional 136,316 shares in the last quarter. Northern Trust Corp raised its holdings in Sanofi by 2.3% in the 2nd quarter. Northern Trust Corp now owns 2,209,626 shares of the company’s stock worth $88,407,000 after purchasing an additional 49,233 shares in the last quarter. Finally, Hamlin Capital Management LLC raised its holdings in Sanofi by 16.7% in the 2nd quarter. Hamlin Capital Management LLC now owns 2,066,689 shares of the company’s stock worth $82,688,000 after purchasing an additional 295,930 shares in the last quarter. Institutional investors own 7.54% of the company’s stock.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
See Also: Dividend
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.